In a single-arm phase II KEYNOTE-052 clinical trial, pembrolizumab was shown to have a durable clinical response in cisplatin-intolerant patients with advanced bladder cancer and was associated with prolonged overall survival, particularly in patients with high PD-L1 expression [10]. This evidence concerns the gene CD274 and urinary bladder carcinoma.